Shots:
- Pfizer has entered into a definitive agreement to acquire Metsera, expanding to obesity & cardiometabolic market
- As per the deal, Metsera will receive $47.5/share, representing an enterprise value of ~$4.9B, plus a non-transferable CVR of ~$22.50/share tied to milestones: $5 on P-III start of MET-097i + MET-233i, $7 on FDA approval for MET-097i monotx., & $10.5 on FDA approval for MET-097i + MET-233i (QM); closing expected in Q4’25
- Metsera’s pipeline incl. 4 clinical programs & various preclinical assets, incl. MET-097i (QW/QM, GLP-1 receptor agonist) in P-II, MET-233i (QM, amylin analog) ± MET-097i in P-I, 2 GLP-1 receptor agonist (PO) & preclinical hormone therapies
Ref: Pfizer | Image: Metsera | Press Release
Related News:- Biogen to Acquire Alcyone Therapeutics to expand its drug delivery solutions Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
